Even with 2025 seeing ADCs rival oncology standard of care performance and multiple new regulatory approvals, clinical toxicity still remains the largest hurdle to widen ADC therapeutic index and accomplish widespread impact for patients

Don’t miss this important seminar spanning the breadth of ADC toxicity including in vivo and in vitro model to predict clinical tolerability, harnessing masked payload technology to improve off-target toxicity and clinical mitigation strategies to deliver safer, more effective ADCs